Načítá se...
Opinion: miRNAs – The new wave of molecular cancer therapeutics
Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how...
Uloženo v:
| Vydáno v: | Transl Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Neoplasia Press
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7957095/ https://ncbi.nlm.nih.gov/pubmed/33721829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101064 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|